Evidence map›Paper›PMID 38240416›Full record

Trial reportEuropean journal of neurology2024

In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis.

Joachim Schuster, Jens Dreyhaupt, Karla Mönkemöller, Luc Dupuis, Stéphane Dieterlé, Jochen H Weishaupt, Jan Kassubek, Susanne Petri, Thomas Meyer, Julian Grosskreutz and 15 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. Prevalence and impact of comorbidities in amyotrophic lateral sclerosis.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. G-Quadruplexes Abet Neuronal Burnout in ALS and FTD.Antioxidants (Basel, Switzerland) · 2025
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 15 institutions in 3 countries.

Joachim SchusterDepartment of Neurology, University of Ulm, Ulm, Germany.ORCID https://orcid.org/0000-0002-9577-9541
Jens DreyhauptInstitute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
Karla MönkemöllerDepartment of Clinical and Health Psychology, Institute of Education and Psychology, University of Ulm, Ulm, Germany.
Luc DupuisUniversité de Strasbourg, Inserm, UMR-S1118, Centre de Recherches en biomédecine de Strasbourg, Strasbourg, France.
Stéphane DieterléUniversité de Strasbourg, Inserm, UMR-S1118, Centre de Recherches en biomédecine de Strasbourg, Strasbourg, France.
Jochen H WeishauptDivision of Neurodegeneration, Department of Neurology, Mannheim Center for Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Jan KassubekDepartment of Neurology, University of Ulm, Ulm, Germany.ORCID https://orcid.org/0000-0002-7106-9270
Susanne PetriDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Thomas MeyerDepartment of Neurology, Center for ALS and other Motor Neuron Disorders, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.ORCID https://orcid.org/0000-0002-2736-7350
Julian GrosskreutzDepartment of Neurology, University Clinic Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Berthold SchrankDepartment of Neurology, DKD HELIOS Klinik Wiesbaden, Wiesbaden, Germany.
Matthias BoentertDepartment of Neurology, University Hospital Münster, Münster, Germany.
Alexander EmmerDepartment of Neurology, University Hospital Halle, Halle, Germany.
Andreas HermannTranslational Neurodegeneration Section "Albrecht Kossel," Department of Neurology, University Medical Center Rostock, Rostock, Germany.
Daniel ZellerDepartment of Neurology, University of Würzburg, Würzburg, Germany.ORCID https://orcid.org/0000-0003-3393-5657
Johannes PrudloGerman Center for Neurodegenerative Diseases, Rostock/Greifswald, Rostock, Germany.
Andrea S WinklerDepartment of Neurology, Technical University Munich, Munich, Germany.
Torsten GrehlDepartment of Neurology, Alfried Krupp Hospital, Essen, Germany.
Michael T HenekaLuxembourg Center for Systems Biomedicine, University of Luxembourg, Belval, Luxembourg.
Siw JohannesenNeurology, BG Hospital Murnau, Murnau, Germany.
Bettina GörickeDepartment of Neurology, University Hospital of Göttingen, Göttingen, Germany.
Simon WitzelDepartment of Neurology, University of Ulm, Ulm, Germany.ORCID https://orcid.org/0000-0003-1841-954X
Johannes DorstDepartment of Neurology, University of Ulm, Ulm, Germany.ORCID https://orcid.org/0000-0001-6352-0909
Albert C LudolphDepartment of Neurology, University of Ulm, Ulm, Germany.
RAS-ALS Study Group
Universität Ulm · DEGerman Center for Neurodegenerative Diseases · DEInserm · FRAlfried Krupp Hospital · DEBerufsgenossenschaftliche Unfallklinik Murnau · DEHeidelberg University · DEHumboldt-Universität zu Berlin · DEMedizinische Hochschule Hannover · DETechnical University of Munich · DEUniversitätsmedizin Göttingen · DEUniversity Hospital in Halle · DEUniversity Hospital Münster · DEUniversity Hospital Schleswig-Holstein · DEUniversity of Luxembourg · LUUniversity of Würzburg · DE

Funding

Teva Pharmaceutical Industries
6 · The paper itself

Abstract

background and purposeIn 2016, we concluded a randomized controlled trial testing 1 mg rasagiline per day add-on to standard therapy in 252 amyotrophic lateral sclerosis (ALS) patients. This article aims at better characterizing ALS patients who could possibly benefit from rasagiline by reporting new subgroup analysis and genetic data.

methodsWe performed further exploratory in-depth analyses of the study population and investigated the relevance of single nucleotide polymorphisms (SNPs) related to the dopaminergic system.

resultsPlacebo-treated patients with very slow disease progression (loss of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised [ALSFRS-R] per month before randomization of ≤0.328 points) showed a per se survival probability after 24 months of 0.85 (95% confidence interval = 0.65-0.94). The large group of intermediate to fast progressing ALS patients showed a prolonged survival in the rasagiline group compared to placebo after 6 and 12 months (p = 0.02, p = 0.04), and a reduced decline of ALSFRS-R after 18 months (p = 0.049). SNP genotypes in the MAOB gene and DRD2 gene did not show clear associations with rasagiline treatment effects.

conclusionsThese results underline the need to consider individual disease progression at baseline in future ALS studies. Very slow disease progressors compromise the statistical power of studies with treatment durations of 12-18 months using clinical endpoints. Analysis of MAOB and DRD2 SNPs revealed no clear relationship to any outcome parameter. More insights are expected from future studies elucidating whether patients with DRD2

Indexed as

Amyotrophic Lateral SclerosisDisease ProgressionHumansIndansIndansrasagilineamyotrophic lateral sclerosisrandomized controlled trialrasagilinesubgroup analysis

Identifiers

PMID38240416
PMCPMC11235627
OpenAlexW4391025965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.